Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation

Liver Transplantation

Volumn 19, Issue 1, 2013, Pages 3-26

  Lucey, Michael R ^a   Terrault, Norah ^b   Ojo, Lolu ^c   Hay, J Eileen ^d   Neuberger, James ^e   Blumberg, Emily ^f   Teperman, Lewis W ^g  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MAYO CLINIC   (United States)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMLODIPINE; AMPHOTERICIN B LIPID COMPLEX; ATOVAQUONE; BISPHOSPHONIC ACID DERIVATIVE; CASPOFUNGIN; COTRIMOXAZOLE; DAPSONE; DILTIAZEM; EVEROLIMUS; FENOFIBRATE; FLUCONAZOLE; GANCICLOVIR; GEMFIBROZIL; GLIMEPIRIDE; GLIPIZIDE; IBANDRONIC ACID; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; ITRACONAZOLE; METFORMIN; MYCOPHENOLIC ACID; NIFEDIPINE; OMEGA 3 FATTY ACID; RAPAMYCIN; SULFONYLUREA; UNINDEXED DRUG; VALGANCICLOVIR; VERAPAMIL; ZOLEDRONIC ACID;

ACUTE LIVER FAILURE; ADD ON THERAPY; ALCOHOL LIVER DISEASE; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BONE DENSITY; BONE DISEASE; BONE MARROW SUPPRESSION; BONE REMODELING; CAVA VEIN OBSTRUCTION; CHRONIC KIDNEY DISEASE; CYTOMEGALOVIRUS INFECTION; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; END STAGE LIVER DISEASE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; GRAFT RECIPIENT; GRAFT SURVIVAL; HEALTH PROMOTION; HEPATIC ARTERY THROMBOSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LATENT TUBERCULOSIS; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LONG TERM CARE; LUNG FIBROSIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; METABOLIC SYNDROME X; MYCOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOPOROSIS; PATIENT MONITORING; PERIPHERAL EDEMA; PNEUMOCYSTOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; RESISTANCE TRAINING; RETRANSPLANTATION; SMOKING; SODIUM RESTRICTION;

ADULT; BONE DENSITY; END STAGE LIVER DISEASE; GRAFT REJECTION; HEALTH PROMOTION; HUMANS; LIVER TRANSPLANTATION; MORBIDITY; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84872001081     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23566     Document Type: Article

References (115)

1. Eddy DM,. A Manual for Assessing Health Practices and Designing Practice Guidelines. Philadelphia, PA: American College of Physicians; 1996.
2. Committee to Advise the Public Health Service on Clinical Practice Guidelines, Institute of Medicine;, Field MJ, Lohr KN, eds. Clinical Practice Guidelines: Directions of a New Program. Washington, DC: National Academies Press; 1990.
3. American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995; 108: 925-926.
4. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ,; for GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926. (Pubitemid 351632017)
5. Devlin J, Doherty D, Thomson L, Wong T, Donaldson P, Portmann B, Williams R,. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926-933. (Pubitemid 28160476)
6. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940. (Pubitemid 37064766)
7. Tome S, Wells JT, Said A, Lucey MR,. Quality of life after liver transplantation. A systematic review. J Hepatol 2008; 48: 567-577.
8. Shah JN, Haigh WG, Lee SP, Lucey MR, Brensinger CM, Kochman ML, et al. Biliary casts after orthotopic liver transplantation: clinical factors, treatment, biochemical analysis. Am J Gastroenterol 2003; 98: 1861-1867. (Pubitemid 36959171)
9. Safdar N, Said A, Lucey MR, Knechtle SJ, D'Alessandro A, Musat A, et al. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality. Clin Infect Dis 2004; 39: 517-525. (Pubitemid 39120927)
10. Banff Working Group, Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489-501. (Pubitemid 44214890)
11. Musat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
12. Guichelaar MM, Kendall R, Malinchoc M, Hay JE,. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006; 12: 1390-1402. (Pubitemid 44405129)
13. Guichelaar MM, Schmoll J, Malinchoc M, Hay JE,. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology 2007; 46: 1198-1207. (Pubitemid 350144784)
14. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB,. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934-1939. (Pubitemid 34027867)
15. Paramesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant 2004; 18: 94-99. (Pubitemid 38195551)
16. Gonwa TA, McBride MA, Mai ML, Wadei HM,. Kidney transplantation after previous liver transplantation: Analysis of the Organ Procurement Transplant Network database. Transplantation 2011; 92: 31-35.
17. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR,. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420-1427.
18. Wagner D, Kniepeiss D, Stiegler P, Zitta S, Bradatsch A, Robatscher M, et al. The assessment of GFR after orthotopic liver transplantation using cystatin C and creatinine-based equations. Transpl Int 2012; 25: 527-536.
19. Stevens LA, Padala S, Levey AS,. Advances in glomerular filtration rate-estimating equations. Curr Opin Nephrol Hypertens 2010; 19: 298-307.
20. Keane WF, Eknoyan G,. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1004-1010. (Pubitemid 29214705)
21. Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13: 1694-1702.
22. Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial. Liver Transpl 2005; 11: 1064-1072. (Pubitemid 41341755)
23. Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al.; for ReSpECT Study Group. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: The 'ReSpECT' study. Am J Transplant 2009; 9: 327-336.
24. Nair S, Eason J, Loss G,. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9: 126-129. (Pubitemid 36204562)
25. Saner FH, Cicinnati VR, Sotiropoulos G, Beckebaum S,. Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation. Liver Int 2012; 32: 179-188.
26. Demirci G, Becker T, Nyibata M, Lueck R, Bektas H, Lehner F, et al. Results of combined and sequential liver-kidney transplantation. Liver Transpl 2003; 9: 1067-1078. (Pubitemid 37304463)
27. Fabrizi F, Dixit V, Martin P, Messa P,. Chronic kidney disease after liver transplantation: recent evidence. Int J Artif Organs 2010; 33: 803-811.
28. Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S,. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010; 89: 1134-1140.
29. Chen T, Jia H, Li J, Chen X, Zhou H, Tian H,. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int 2009; 22: 408-415.
30. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109-1114. (Pubitemid 47305029)
31. Delgado-Borrego A, Liu YS, Jordan SH, Agrawal S, Zhang H, Christofi M, et al. Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl 2008; 14: 193-201. (Pubitemid 351267276)
32. Demirci MS, Toz H, Yilmaz F, Ertilav M, Asci G, Ozkahya M, et al. Risk factors and consequences of post-transplant diabetes mellitus. Clin Transplant 2010; 24: E170-E177.
33. Heisel O, Heisel R, Balshaw R, Keown P,. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004; 4: 583-595. (Pubitemid 38523581)
34. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.; for National Heart, Lung, and Blood Institute Joint National Committee on Prevention, DetectionEvaluation and Treatment of High Blood Pressure and National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
35. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE,. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 2000; 6: 521-530.
36. Galioto A, Semplicini A, Zanus G, Fasolato S, Sticca A, Boccagni P, et al. Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial. Liver Transpl 2008; 14: 1020-1028. (Pubitemid 352003902)
37. Watt KD, Charlton MR,. Metabolic syndrome and liver transplantation: A review and guide to management. J Hepatol 2010; 53: 199-206.
38. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z,. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011; 17: 15-22.
39. Richards J, Gunson B, Johnson J, Neuberger J,. Weight gain and obesity after liver transplantation. Transpl Int 2005; 18: 461-466. (Pubitemid 41726882)
40. Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH,. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 1998; 4: 285-296. (Pubitemid 28323748)
41. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 1891-1901.
42. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ,. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009; 137: 2010-2017.
43. Finkenstedt A, Graziadei IW, Oberaigner W, Hilbe W, Nachbaur K, Mark W, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant 2009; 9: 2355-2361.
44. Herrero JI, Pardo F, D'Avola D, Alegre F, Rotellar F, Iñarrairaegui M, et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: The effect of smoking withdrawal. Liver Transpl 2011; 17: 402-408.
45. Nishihori T, Strazzabosco M, Saif MW,. Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer 2008; 7: 260-266.
46. Simon S,. New screening guidelines for cervical cancer. http://www.cancer.org/Cancer/news/new-screening-guidelines-for-cervical-cancer. Published March 14, 2012. Accessed October 2012.
47. Roberts JP,. Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2005; 11 (suppl 2): S45-S46. (Pubitemid 43072614)
48. Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis. Liver Transpl 2012; 18: 62-69.
49. Mass K, Quint EH, Punch MR, Merion RM,. Gynecological and reproductive function after liver transplantation. Transplantation 1996; 62: 476-479. (Pubitemid 26295822)
50. Cundy TF, O'Grady JG, Williams R,. Recovery of menstruation and pregnancy after liver transplantation. Gut 1990; 31: 337-338. (Pubitemid 20093675)
51. Armenti VT, Radomski JS, Moritz MJ, Gaughan WJ, Gulati R, McGrory CH, Coscia LA,. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2005: 69-83.
52. Burra P, Germani G, Masier A, De Martin E, Gambato M, Salonia A, et al. Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure? Transplantation 2010; 89: 1425-1429.
53. Ho JK, Ko HH, Schaeffer DF, Erb SR, Wong C, Buczkowski AK, et al. Sexual health after orthotopic liver transplantation. Liver Transpl 2006; 12: 1478-1484. (Pubitemid 44594277)
54. Coffin CS, Shaheen AA, Burak KW, Myers RP,. Pregnancy outcomes among liver transplant recipients in the United States: A nationwide case-control analysis. Liver Transpl 2010; 16: 56-63.
55. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT,. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006; 82: 1698-1702. (Pubitemid 46035654)
56. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA,. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 2009; 149A: 1241-1248.
57. Heneghan MA, Selzner M, Yoshida EM, Mullhaupt B,. Pregnancy and sexual function in liver transplantation. J Hepatol 2008; 49: 507-519.
58. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 2002; 17 (suppl 4): 50-55.
59. Christopher V, Al-Chalabi T, Richardson PD, Muiesan P, Rela M, Heaton ND, et al. Pregnancy outcome after liver transplantation: A single-center experience of 71 pregnancies in 45 recipients. Liver Transpl 2006; 12: 1138-1143. (Pubitemid 44063790)
60. San Juan R, Aguado JM, Lumbreras C, Díaz-Pedroche C, López-Medrano F, Lizasoain M, et al.; for RESITRA Network (Spain). Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007; 7: 964-971. (Pubitemid 46481186)
61. Humar A, Snydman D,; for AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S78-S86.
62. Razonable RR,. Cytomegalovirus infection after liver transplantation. Liver Transpl 2010; 16 (suppl 2): S45-S53.
63. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al.; for Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
64. Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, et al.; for VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106-2113. (Pubitemid 47247057)
65. Burra P, Buda A, Livi U, Rigotti P, Zanus G, Calabrese F, et al. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: Any role for hepatitis C infection? Eur J Gastroenterol Hepatol 2006; 18: 1065-1070. (Pubitemid 44379359)
66. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: A 20-year experience. Ann Surg 2002; 236: 429-436.
67. Allen U, Preiksaitis J,; for AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S87-S96.
68. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM,. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006; 6 (pt 1): 1017-1024. (Pubitemid 44356653)
69. Koch DG, Christiansen L, Lazarchick J, Stuart R, Willner IR, Reuben A,. Posttransplantation lymphoproliferative disorder-the great mimic in liver transplantation: Appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl 2007; 13: 904-912. (Pubitemid 46947851)
70. Singh N, Wagener MM, Marino IR, Gayowski T,. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002; 73: 63-67. (Pubitemid 34094686)
71. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ,. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993; 17: 103-109. (Pubitemid 23294544)
72. Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB,. The (1,3)β- D -glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 2010; 48: 4083-4088.
73. Hope WW, Walsh TJ, Denning DW,. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5: 609-622. (Pubitemid 41383906)
74. Fortún J, Martín-Dávila P, Alvarez ME, Norman F, Sánchez-Sousa A, Gajate L, et al. False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipients. Transplantation 2009; 87: 256-260.
75. Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S,. Cryptococcal meningitis: An analysis among 5,521 consecutive organ transplant recipients. Transpl Infect Dis 2002; 4: 183-188. (Pubitemid 36142803)
76. Durkin M, Witt J, Lemonte A, Wheat B, Connolly P,. Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol 2004; 42: 4873-4875. (Pubitemid 39362430)
77. Connolly PA, Durkin MM, Lemonte AM, Hackett EJ, Wheat LJ,. Detection of Histoplasma antigen by a quantitative enzyme immunoassay. Clin Vaccine Immunol 2007; 14: 1587-1591.
78. Martin SI, Fishman JA,; for AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S227-S233.
79. Aguado JM, Torre-Cisneros J, Fortún J, Benito N, Meije Y, Doblas A, Muñoz P,. Tuberculosis in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48: 1276-1284.
80. Subramanian A, Dorman S,; for AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S57-S62.
81. Yehia BR, Blumberg EA,. Mycobacterium tuberculosis infection in liver transplantation. Liver Transpl 2010; 16: 1129-1135.
82. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al.; for American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
83. Blumberg EA, Stock P,; for AST Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient. Am J Transplant 2009; 9 (suppl 4): S131-S135.
84. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816-2820. (Pubitemid 350045781)
85. Castells L, Escartín A, Bilbao I, Len O, Allende H, Vargas V, et al. Liver transplantation in HIV-HCV coinfected patients: A case-control study. Transplantation 2007; 83: 354-358.
86. Danzinger-Isakov L, Kumar D,; for AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 (suppl 4): S258-S262.
87. Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL,. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137: 1680-1686.
88. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G,. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696-700.
89. Rao W, Wu X, Xiu D,. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: A meta-analysis. Transpl Int 2009; 22: 387-394.
90. Katz LH, Paul M, Guy DG, Tur-Kaspa R,. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010; 12: 292-308.
91. Dan YY, Wai CT, Yeoh KG, Lim SG,. Prophylactic strategies for hepatitis B patients undergoing liver transplant: A cost-effectiveness analysis. Liver Transpl 2006; 12: 736-746.
92. Fox AN, Terrault NA,. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol 2012; 56: 1189-1197.
93. Lucey MR, Graham DM, Martin P, Di Bisceglie A, Rosenthal S, Waggoner JG, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33: 1390-1396.
94. Terrault NA, Berenguer M,. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192-1204. (Pubitemid 44194586)
95. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (pt 1): 852-858.
96. Kalambokis G, Manousou P, Samonakis D, Grillo F, Dhillon AP, Patch D, et al. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int 2009; 22: 172-181.
97. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896. (Pubitemid 34267271)
98. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P,. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. Transplantation 2004; 77: 226-231. (Pubitemid 38155751)
99. Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH,. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5: 549-557. (Pubitemid 40313347)
100. Wiesner RH, Sorrell M, Villamil F,; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9. (Pubitemid 37407996)
101. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008; 8: 2426-2433.
102. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
103. Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, Schiano TD,. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008; 14: 861-871. (Pubitemid 351895516)
104. Neuberger J,. Recurrent primary biliary cirrhosis. Liver Transpl 2003; 9: 539-546. (Pubitemid 36701687)
105. Hubscher SG, Elias E, Buckels JA, Mayer AD, McMaster P, Neuberger JM,. Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation. J Hepatol 1993; 18: 173-184. (Pubitemid 23246944)
106. Neuberger J, Gunson B, Hubscher S, Nightingale P,. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004; 10: 488-491. (Pubitemid 38443587)
107. Joshi D, Bjarnason I, Belgaumkar A, O'Grady J, Suddle A, Heneghan MA, et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int; doi:10.111/j1478- 3231.2011.02677.
108. Fosby B, Karlsen TH, Melum E,. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012; 18: 1-15.
109. Tripathi D, Neuberger J,. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis 2009; 29: 286-296.
110. Lucey MR,. Liver transplantation in patients with alcoholic liver disease. Liver Transpl 2011; 17: 751-759.
111. DiMartini A, Dew MA, Chaiffetz D, Fitzgerald MG, Devera ME, Fontes P,. Early trajectories of depressive symptoms after liver transplantation for alcoholic liver disease predicts long-term survival. Am J Transplant 2011; 11: 1287-1295.
112. Angulo P,. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006; 12: 523-534.
113. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, et al. Non-alcoholic fatty liver disease in liver transplant recipients: Another story of "seed and soil". Am J Gastroenterol 2010; 105: 613-620.
114. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7: 608-614. (Pubitemid 32677885)
115. Dureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A,. NAFLD recurrence in liver transplant recipients. Transplantation 2011; 91: 684-689.